Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › OASIS 4

OASIS 4

Semaglutide · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Semaglutide
Population
obesity
Official title
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
Sponsor
Novo Nordisk A/S
Phase
3
Registry status
completed · 2022-10 → 2024-04
Participants
307
Duration
64 weeks
Registry
NCT05564117

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
oral semaglutide 25 mgobesity64307−16.6 % vs −2.7 %
Δ −13.9 pp
−13.6 % vs −2.2 %
Δ −11.4 pp
−0.3 vs −0.16.9 vs 5.918.5 vs 25.546.6 vs 18.630.9 vs 5.93.9 vs 8.8−6.8 vs −5.4verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (7)
  • oral semaglutide 25 mg · ae_dc · Table 3
    Adverse events leading to discontinuation of semaglutide or placebo 14 (6.9) 14 5.6 6 (5.9)
  • oral semaglutide 25 mg · disc_any · Results, Participants
    243 participants (79.2%) were receiving sema- glutide or placebo at the end of the 64-week trial period — 167 (81.5%) in the oral semaglutide group and 76 (74.5%) in the placebo group; 290
  • oral semaglutide 25 mg · nausea · Table 3
    Nausea 95 (46.6) 157 62.5 19 (18.6) 27 22.2
  • oral semaglutide 25 mg · vomiting · Table 3
    Vomiting 63 (30.9) 105 41.8 6 (5.9) 6 4.9
  • oral semaglutide 25 mg · sae · Table 3
    Serious adverse events 8 (3.9) 17 6.8 9 (8.8) 13 10.7
  • oral semaglutide 25 mg · hba1c · Table 2
    Glycated hemoglobin — percentage points –0.3 –0.1 –0.2 (–0.3 to –0.2)
  • oral semaglutide 25 mg · sbp · Table 2
    Systolic blood pressure — mm Hg –6.8 –5.4 –1.4 (–4.6 to 1.8)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: OASIS 4. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/oasis-4/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.